A powerful EGFR tyrosine kinase inhibitor, osimertinib drug, has become a cornerstone in the treatment of late-stage non-small cell lung cancer (NSCLC) in recent years.This precision therapy, however, is not without its difficulties, notably the occurrence of osimertinib drug immunodepression.The first paragraph delves into the importance of knowledge and handling osimertinib drug-induced immunodepression in the context of non-small cell lung cancer treatment.osimertinib drug-Induced immunodepression: risk evaluation and MonitoringThe accurate identification of patients at risk is the first critical aspect in handling osimertinib drug immunodepression. Factors such as age, comorbidities, and…
